Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for pneumonia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pneumonia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on pneumonia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen.Comparative observational study using data collected from routine care.Four French tertiary care centres providing care to patients with covid-19 pneumonia between 12 March and 31 March (...) 2020.181 patients aged 18-80 years with documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia who required oxygen but not intensive care.Hydroxychloroquine at a dose of 600 mg/day within 48 hours of admission to hospital (treatment group) versus standard care without hydroxychloroquine (control group).The primary outcome was survival without transfer to the intensive care unit at day 21. Secondary outcomes were overall survival, survival without acute respiratory distress
Management of upper GI bleeding in patients with COVID-19 pneumonia Management of upper GI bleeding in patients with COVID-19 pneumonia Kimberly Cavaliere, 1 Calley Levine, 1 Praneet Wander, 1 Divyesh V Sejpal, 1 Arvind J Trindade 1 1) Division of Gastroenterology, Long Island Jewish Medical Center, Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, New Hyde Park, NY, USA ADDRESS CORRESPONDENCE: Dr. Arvind J. Trindade Director of Endoscopy Long Island Jewish Medical Center (...) to our hospital with COVID-19 –associated pneumonia (fever, shortness of breath requiring oxygen, positive COVID-19 polymerase chain reaction [PCR] test, and infiltrates showing on chest radiograph), and upper GI bleeding. The patient and clinical characteristics can be found in Table 1. The GI manifestations were hematemesis or melena. Guidelines advise that patients who present with acute upper gastrointestinal bleeding undergo endoscopy within 24 hours of presentation 2 . Endoscopy can not only
BTS guidance on respiratory follow up of patients with radiologically confirmed COVID-19 pneumonia V1.2 11 May 2020 1 British Thoracic Society Guidance on Respiratory Follow Up of Patients with a Clinico-Radiological Diagnosis of COVID-19 Pneumonia Introduction This guidance outlines British Thoracic Society (BTS) recommended follow up of patients with a clinico-radiological diagnosis of COVID-19 pneumonia. The COVID-19 swab status of patients is not relevant to this guidance. The entry point (...) to this guidance is a clinical diagnosis of COVID-19 pneumonia with consistent radiological changes. This document may require updating as more information becomes available. This version was published on Monday 11 May 2020. Please check the BTS website for the most up to date version of this document. This guidance focuses on the radiological follow up of the pneumonic process and the subsequent diagnosis and management of respiratory complications of COVID-19 pneumonia. This guidance is intended
Do Corticosteroids Benefit Patients With Influenza Pneumonia? Do Corticosteroids Benefit Patients With Influenza Pneumonia? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page To read this article in full, please review your options for gaining access at the bottom of the page. Article in Press Do Corticosteroids Benefit Patients With Influenza Pneumonia? x Michael Gottlieb , MD (EBEM Commentator) , x Thomas Seagraves , MD (EBEM (...) Commentator) , x Stephen R. Gore , MD (EBEM Commentator) Department of Emergency Medicine, Rush University Medical Center, Chicago, IL DOI: Publication History Published online: July 23, 2019 To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Among patients with influenza pneumonia, corticosteroids are associated with increased mortality, longer length of stay in the ICU, and higher rates of secondary infection, although there are no data from
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The initial cases of novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, Hubei Province, China, in December 2019 and January 2020. We analyzed data on the first 425 confirmed cases in Wuhan to determine the epidemiologic characteristics of NCIP.We collected information on demographic characteristics, exposure history, and illness timelines of laboratory-confirmed cases of NCIP that had
A Novel Coronavirus from Patients with Pneumonia in China, 2019. In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia. Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. In December, 2019, a pneumonia associated with the 2019 novel coronavirus (2019-nCoV) emerged in Wuhan, China. We aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia.In this retrospective, single-centre study, we included all confirmed cases of 2019-nCoV in Wuhan Jinyintan Hospital from Jan 1 to Jan 20, 2020. Cases were (...) confirmed by real-time RT-PCR and were analysed for epidemiological, demographic, clinical, and radiological features and laboratory data. Outcomes were followed up until Jan 25, 2020.Of the 99 patients with 2019-nCoV pneumonia, 49 (49%) had a history of exposure to the Huanan seafood market. The average age of the patients was 55·5 years (SD 13·1), including 67 men and 32 women. 2019-nCoV was detected in all patients by real-time RT-PCR. 50 (51%) patients had chronic diseases. Patients had clinical
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. An ongoing outbreak of pneumonia associated with a novel coronavirus was reported in Wuhan city, Hubei province, China. Affected patients were geographically linked with a local wet market as a potential source. No data on person-to-person or nosocomial transmission have been published to date.In this study, we report the epidemiological, clinical (...) , laboratory, radiological, and microbiological findings of five patients in a family cluster who presented with unexplained pneumonia after returning to Shenzhen, Guangdong province, China, after a visit to Wuhan, and an additional family member who did not travel to Wuhan. Phylogenetic analysis of genetic sequences from these patients were done.From Jan 10, 2020, we enrolled a family of six patients who travelled to Wuhan from Shenzhen between Dec 29, 2019 and Jan 4, 2020. Of six family members who
Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator- associated pneumonia Evidence summary Published: 18 December 2019 www.nice.org.uk/guidance/es22 pathways K Ke ey messages y messages The content of this evidence review was up-to-date in December 2019. See summaries of product (...) /tazobactam for more information). In August 2019, the indication for ceftolozane with tazobactam was extended to include treating hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) in adults (Zerbaxa: Procedural steps taken and scientific information after authorisation). Evidence for using ceftolozane with tazobactam for treating HAP and VAP is from 1 phase 3 randomised controlled non-inferiority trial (ASPECT-NP). ASPECT-NP found that a high dose of ceftolozane
Rapid diagnosis strategy of community-acquired pneumonia for clinicians Rapid diagnosis strategy of community-acquired pneumonia for clinicians - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Rapid diagnosis strategy of community-acquired pneumonia for clinicians PDF to download Annette Pluddemann, Richard Hobbs, Kamal R. Mahtani and Carl Heneghan On behalf of the Oxford COVID-19 Evidence Service Team (...) Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford Correspondence to VERDICT: Based on the best available evidence, a restricted strategy may be suitable for diagnosing pneumonia in the community. Such a strategy may be particularly suitable during the current Covid-19 pandemic where resources may be stretched. RECOMMENDED APPROACH IN EMERGENCY SITUATION Key equipment includes pulse oximeter,* a thermometer, and stethoscope (along
Covid-19: Differentiating viral from bacterial pneumonia Differentiating viral from bacterial pneumonia - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Differentiating viral from bacterial pneumonia April 8, 2020 Carl Heneghan, Annette Pluddemann and Kamal R. Mahtani On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health (...) Sciences University of Oxford Correspondence to VERDICT A severe complication of COVID-19 is viral pneumonia. Distinguishing viral pneumonia from bacterial pneumonia is difficult in the community. In some cases, they could co-exist, increasing the chance of a more unfortunate outcome. However, there may be important clues in the history and the examination that can help differentiate the two. Recent guidance from NICE (UK) will support clinicians in this process. BACKGROUND Community-acquired pneumonia
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) POSITION ARTICLE AND GUIDELINE Open Access A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Ying-Hui Jin 1 , Lin Cai 2 , Zhen-Shun Cheng 3 , Hong Cheng 4 , Tong Deng 1,5 , Yi-Pin Fan 6,7 , Cheng Fang 1 , Di Huang 1 , Lu-Qi Huang 6,7 , Qiao Huang 1 , Yong Han 2 ,BoHu 8 , Fen Hu 8 (...) 1,18* , Yong-Yan Wang 6,7* , Xing-Huan Wang 1,2* , for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM) Abstract In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named “2019 novel coronavirus (2019-nCoV)” by the World Health Organization (WHO) on 12 January 2020. For it is a never been
COVID-19: Rapidly managing pneumonia in older people during a pandemic Rapidly managing pneumonia in older people during a pandemic - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Rapidly managing pneumonia in older people during a pandemic Carl Heneghan, Jeff Aronson, Kamal Mahtani Rationale The current has highlighted the risk faced by older adults, who are more susceptible to complications, including (...) , usually as a result of pneumonia. Comorbidities, impaired immunity and frailty, including a reduced ability to cough and to clear secretions from the lungs, can all contribute to this complication. Older people are therefore more likely to develop severe pneumonia, suffer from respiratory failure, and die. Viruses are thought to cause about 50% of cases of pneumonia. Viral pneumonia is generally less severe than bacterial pneumonia but can act as a precursor to it. Preventing any pneumonia in older
Ceftolozane/tazobactam (Zerbaxa) - hospital acquired pneumonia, including ventilator-associated pneumonia Published 09 December 2019 1 Statement of advice SMC2256 ceftolozane / tazobactam 1g/0.5g powder for concentrate for solution for infusion (Zerbaxa®) Merck Sharp & Dohme Limited 8 November 2019 ADVICE: in the absence of a submission from the holder of the marketing authorisation ceftolozane / tazobactam (Zerbaxa®) is not recommended for use within NHSScotland. Indication under review (...) : In adults for the treatment of hospital acquired pneumonia, including ventilator-associated pneumonia. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration